Comments
Drug firm Zydus Cadila today said it has received a final nod from the US health regulator to market Donepezil Hydrochloride tablets used for the treatment of dementia of the Alzheimer’s type in the American market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Donepezil Hydrochloride tablets in the strength of 23 mg, Zydus Cadila said in a statement.
The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya in Ahmedabad, Zydus Cadila said.
The tablets are indicated for the treatment of dementia of Alzheimer’s disease, it added.
The group now has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process, Zydus Cadila said.
Shares of Cadila Healthcare, the listed entity of the group, were today trading 1.25 per cent higher at Rs 506.35 per scrip on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.